Mounjaro BMI Cutoffs in the UK:
Why Stopping Too Early Can Backfire

BMI (Body Mass Index) is the most widely used tool for classifying weight in UK clinical practice—and it underpins the eligibility criteria for Mounjaro and other weight management treatments. But BMI has well-documented limitations as a standalone measure of health.

BMI does not measure:

• Muscle mass — a highly muscular person may have a 'high' BMI without excess fat
• Fat distribution — where fat is stored (visceral vs subcutaneous) is clinically more significant than total weight
• Metabolic health — blood sugar, insulin sensitivity, cholesterol, and cardiovascular risk are not captured by BMI
• Weight history — someone who has lost 20% of their body weight from a high starting point may still carry significant metabolic risk

The NHS acknowledges that BMI should be used alongside broader clinical assessment—not as a standalone determinant of health or treatment decisions.

A foundational shift in how the medical community understands obesity is recognising it as a chronic, relapsing condition—not a temporary problem solved by a course of medication.

This is increasingly supported by clinical evidence. The SURMOUNT-4 trial specifically studied what happens when patients stop tirzepatide after achieving weight loss. The results were stark: patients who discontinued tirzepatide regained approximately two-thirds of their lost weight within 12 months, while those who continued lost an additional 6%.

This is not a personal failing—it is the pharmacological reality of how GLP-1 medications work. They suppress appetite and regulate metabolism while active. When stopped, hunger returns to its previous biological set point.

GLP-1 medications like Mounjaro regulate appetite, support insulin sensitivity, and help maintain metabolic rate during weight loss. Stopping them abruptly reverses all of these effects simultaneously.

A structured maintenance approach—rather than abrupt cessation—is aligned with how other chronic conditions are managed:

• Blood pressure — patients are not taken off antihypertensives once their blood pressure normalises; the medication is often continued to maintain the improvement.
• Type 2 diabetes — insulin and other medications are maintained or adjusted based on ongoing clinical need, not removed because glucose levels improve.
• Mental health — antidepressants are typically maintained for a period after symptom resolution to prevent relapse.

The same logic applies to Mounjaro. The underlying biological drivers of obesity—appetite regulation, insulin sensitivity, metabolic rate—do not permanently resolve because a treatment target has been reached.

Discontinuing Mounjaro prematurely—particularly based solely on a BMI threshold—carries real clinical risks:

• Return of hunger and cravings — appetite suppression reverses within weeks of stopping
• Rapid weight regain — SURMOUNT-4 data shows ~two-thirds of lost weight regained within 12 months
• Metabolic disruption — improvements in blood sugar, cholesterol, and blood pressure may reverse
• Cardiovascular risk rebound — the protective effects demonstrated in GLP-1 cardiovascular trials depend on continued treatment
• Reduced motivation and treatment confidence — yo-yo weight cycles are psychologically and physiologically harmful

Rather than applying rigid BMI cutoffs, a more clinically appropriate approach to long-term Mounjaro management includes:

• Gradual dose reduction — rather than abrupt cessation, stepping down from the active treatment dose to a lower maintenance dose reduces the severity of appetite rebound and weight regain.
• Long-term maintenance plans — a structured plan that defines when and how treatment will be reviewed, what constitutes successful maintenance, and what triggers a return to active treatment.
• Ongoing monitoring — regular review of weight, metabolic markers, and patient-reported outcomes, rather than a binary prescribe/stop decision.

This approach is consistent with both the NICE TA1026 guidance, which recommends tirzepatide for up to two years with clinical review, and with pharmaceutical guidance from Eli Lilly, which supports ongoing treatment where clinically appropriate rather than abrupt discontinuation.

Not all UK providers approach long-term Mounjaro management the same way. Some apply rigid BMI eligibility criteria that result in patients losing access to treatment once they reach a 'normal' BMI—even when clinical need continues.

When evaluating providers, ask specifically about:

• Continuation policies — what happens to your prescription if your BMI falls below the standard eligibility threshold?
• Maintenance programmes — do they offer lower-dose maintenance prescribing for patients who have achieved their target weight?
• Flexible BMI thresholds — do they consider weight history and metabolic health, not just current BMI?
• Long-term prescribing and clinical support — is there ongoing monitoring beyond the initial weight loss phase?

All pharmacies offering Mounjaro must be registered with the General Pharmaceutical Council (GPhC). See our guide on local vs online pharmacies for Mounjaro and how to switch pharmacies if you need a provider better suited to long-term management.